Advertisement
Table 1 Patient characteristics by study groups
| Parameters | cisplatin (N = 137) | carboplatin (N = 76) | P-value |
|---|---|---|---|
| Age (years) | 51.6 (21–67) | 53.8 (35–70) | 0.051 |
| Maximal diameter of primary tumor(cm) | 4.5 (2–8) | 4.3(2–9) | 0.4 |
| Stage | 0.09 | ||
| IIB | 91(66.4 %) | 43(56.6 %) | |
| IIIA | 0 | 2(2.6 %) | |
| IIIB | 44(32.1 %) | 31(40.8 %) | |
| IVA | 2(1.5 %) | 0 | |
| Pelvic Lymph nodes | 0.63 | ||
| No | 72(52.6 %) | 45(59.2 %) | |
| Yes | 14(10.2 %) | 6(7.9 %) | |
| Unknown | 51(37.2 %) | 25(32.9 %) | |
| Histology | 0.4 | ||
| SCCA | 114(83.2 %) | 66(86.8 %) | |
| ACA | 21(15.3 %) | 9(11.8 %) | |
| Others | 2(1.5 %) | 1(1.3 %) | |
| Histologic grade | 0.66 | ||
| 1 | 18(14.8 %) | 9(13.4 %) | |
| 2 | 78(63.9 %) | 47(70.1 %) | |
| 3 | 26(21.3 %) | 11(16.4 %) | |
| Cycles | 0.02 | ||
| Up to 4 cycles | 38 (27.7 %) | 10(13.2 %) | |
| 5 to 6 cycles | 99(72.3 %) | 66(86.8 %) | |
| Total treatment time (days) | 56.8 (34–114) | 56(43–173) | 0.39 |
| Median follow-up time (months) | 39.8(6–69) | 40.6(6–69) | 0.76 |
